Biomarker analysis of the phase II JO25567 study comparing erlotinib with or without bevacizumab in first-line advanced EGFR+non-small-cell lung cancer.
Nishio M, Atagi S, Goto K, Hosomi Y, Seto T, Hida T, Nakagawa K, Yoshioka H, Nogami N, Maemondo M, Nagase S, Okamoto I, Yamamoto N, Igawa Y, Tajima K, Fukuoka M, Yamamoto N, Nishio K.
Nishio M, et al. Among authors: igawa y.
Transl Lung Cancer Res. 2023 Jun 30;12(6):1167-1184. doi: 10.21037/tlcr-22-632. Epub 2023 Jun 13.
Transl Lung Cancer Res. 2023.
PMID: 37425411
Free PMC article.